Panitumumab

BNF:

8.1.5

Status:

Do Not Prescribe (DNP), Red

Decision Date:

None

Comments

DO NOT PRESCRIBE (DNP): NICE TA240: Colorectal cancer metastatic. Unable to recommend NHS use - TA terminated due to lack of evidence submission (decision date - January 2012)

DO NOT PRESCRIBE (DNP): NICE TA242: Colorectal cancer (metastatic) 2nd line. Panitumumab – not recommended (decision date - February 2012)

RED ^1,2,3 : NICE TA439 - cetuximab and panitumumab for previously untreated metastatic colorectal cancer. (decision date -  May 2017)

 

(This drug can be funded through the cancer drug fund - seek advice from the oncologist/haematologist)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again